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Abstract
The European Commission asked EFSA to evaluate the efficacy of an infant formula, containing a
specific protein hydrolysate derived from whey protein isolate and concentrate and manufactured by
Societe des Produits Nestle S.A., in reducing the risk of developing atopic dermatitis in infants with a
family history of allergy. This was following the submission of a dossier by Societe des Produits Nestle
S.A. to the European Commission, in the context of Regulation (EU) 2016/127. The protein hydrolysate
from which the infant formula is produced is included in Annex I and II of Commission delegated
Regulation (EU) 2016/127 as suitable protein source for the manufacture of infant and follow-on
formulae. This opinion does not cover the assessment of the nutritional safety and suitability of the
infant formula or the safety of the food enzymes used in the manufacture of the protein hydrolysate.
The Panel considers that, in relation to the effect that is claimed, the infant formula under evaluation is
not sufficiently characterised with respect to the molecular weight distribution of peptides. From the
human intervention studies submitted, no conclusions could be drawn on the efficacy of the infant
formula in reducing the risk of developing atopic dermatitis. The Panel concludes that a cause-and-
effect relationship has not been established between the consumption of the infant formula under
evaluation and the reduction in the risk of developing atopic dermatitis in infants with a family history
of allergy.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background
Commission Directive 2006/141/EC1 lays down harmonised rules applicable in the entire EU to
infant formulae and follow-on formulae. The Directive allows the use of protein hydrolysates as source
of protein in infant formulae and follow-on formulae under certain conditions (Articles 5–7; Annex I,
point 2.2; Annex II, point 2.2 and Annex VI).
Commission delegated Regulation (EU) 2016/1272 transfers the existing rules of Directive 2006/
141/EC under the new framework of Regulation (EU) No 609/2013 of the European Parliament and of
the Council3 and revises them, based on the opinion of the European Food Safety Authority (EFSA) of
2014.4 In that opinion, EFSA noted that ‘the safety and suitability of each specific formula containing
protein hydrolysates has to be established by clinical studies. Information on protein sources and the
technological processes applied should also be provided. In this context, the Panel notes that one
particular formula containing partially hydrolysed whey protein has been evaluated for its safety and
suitability by the Panel (. . .) and has been authorised for use by Directive 2006/141/EC’. EFSA also
noted that ‘the criteria given in Directive 2006/141/EC alone are not sufficient to predict the potential
of a formula to reduce the risk of developing allergy to milk proteins. Clinical studies are necessary to
demonstrate if and to what extent a particular formula reduces the risk of developing short- and long-
term clinical manifestations of allergy in at-risk infants who are not exclusively breast fed’.
Taking into account EFSA’s opinion, the delegated Regulation establishes that infant formula and
follow-on formula manufactured from protein hydrolysates should only be allowed to be placed on the
market if their composition corresponds to the one positively assessed by EFSA so far and prohibits the
use of health claims describing the role of infant formula in reducing the risk of developing allergy to
milk proteins. The requirements of Commission delegated Regulation (EU) 2016/127 shall apply to
infant formula and follow-on formula manufactured from protein hydrolysates from 22 February 2021.
Pursuant to Recital 21 of the Regulation, these requirements may be amended in the future in
order to allow the placing on the market of formulae manufactured from protein hydrolysates with a
composition different from the one already positively assessed, following a case-by-case evaluation of
their safety and suitability by EFSA. In addition, if, after the assessment by EFSA, it is demonstrated
that a specific formula manufactured from protein hydrolysates reduces the risk of developing allergy
to milk proteins, further consideration will be given to how to adequately inform parents and
caregivers about that property of the product.
The requirements of Commission delegated Regulation (EU) 2016/127 shall apply to infant formula
and follow-on formula manufactured from protein hydrolysates from 22 February 2021. It can be
expected that, before that date, dossiers on formulae manufactured from protein hydrolysates will be
presented by food business operators for assessment by EFSA with a view to request possible
modifications to the conditions applicable to these products in the delegated Regulation.
In this context, it is considered necessary to ask EFSA to provide scientific advice to the
Commission on dossiers on formulae manufactured from protein hydrolysates submitted by food
business operators for assessment by EFSA in the future.
EFSA will be informed by the Commission by letter when the applicant has been asked by the
Commission to transmit the dossier to EFSA for scientific assessment.
1 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive
1999/21/EC, OJ L 401, 30.12.2006, p. 1.
2 OJ L 25, 2.2.2016, p. 1.
3 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council
Directive 92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of
the European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009, OJ L 181,
29.6.2013, p. 35.
4 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014. Scientific Opinion on the essential
composition of infant and follow-on formulae. EFSA Journal 2014;12(7):3760.
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1.1.2. Terms of Reference
In accordance with Article 29 of Regulation (EC) No 178/20025, the European Commission requests
the European Food Safety Authority to issue scientific opinions on infant and follow-on formula
manufactured from protein hydrolysates in particular, depending on the nature of the application, on:
1) the safety and suitability for use by infants of a specific formula manufactured from protein
hydrolysates;
If the formula under evaluation is considered to be safe and suitable for use by infants, the
European Food Safety Authority is also asked to advise on the minimum specific criteria on
protein source, protein processing and protein quality of the formula that need to be satisfied
for the safety and suitability of such formulae to be demonstrated.
2) the product’s efficacy in reducing the risk of developing allergy to milk proteins;
3) the product’s efficacy in reducing the risk of developing allergy/allergic manifestations to
allergens in general.
1.2. Interpretation of the Terms of Reference
The interpretation by the Panel on Nutrition, Novel Foods and Food Allergens (NDA) is that
assessment of the safety of food enzymes (or their combination) that are used in the manufacture of
the protein hydrolysate, is not to be assessed in this opinion. The assessment of the safety of the
individual food enzymes is performed by the EFSA Panel on Food Contact Materials, Enzymes and
Processing Aids (CEP) according to the guidance and statements of the CEF/CEP Panel (EFSA CEF
Panel, 2009, 2016, 2019).
The interpretation by the NDA Panel is that the Terms of Reference cover, for this particular dossier,
the assessment of the product’s efficacy in reducing the risk of developing atopic dermatitis in infants
with a family history of allergy, as requested by the food business operator.
Therefore, the conclusions of the Panel are related to the infant formula that was evaluated in the
clinical studies submitted rather than on the specific protein hydrolysate used to manufacture the
infant formula, as constituents of the infant formula other than the protein hydrolysate may also play a
role in modifying the risk of allergic manifestations. The conclusions of the Panel are not related to the
nutritional safety and suitability of the specific protein hydrolysate, the safety of the protein
hydrolysate in general, including the safety of the individual enzymes or their combination, or the
safety of the final formula.
2. Data and methodologies
2.1. Data
The assessment of the efficacy of the infant formula6 in reducing the risk of developing atopic
dermatitis in infants with a family history of allergy is based on the data supplied in the dossier
submitted to EFSA (EFSA-Q-2019-00529) and the additional information provided by the food business
operator upon requests.
A common and structured format for the presentation of dossiers related to infant and follow-on
formula manufactured from protein hydrolysates is described in the EFSA scientific and technical
guidance for the preparation and presentation of an application for authorisation of an infant and/or
follow-on formula manufactured from protein hydrolysates (EFSA NDA Panel, 2017). For the present
assessment, Section 3 in the EFSA guidance related to the nutritional safety and suitability of the
hydrolysed formula is not applicable. As outlined in the guidance, it is the duty of the food business
operator who submitted the dossier to provide all available scientific data which are pertinent to the
dossier. The procedure followed by EFSA for handling dossiers on formulae manufactured from protein
hydrolysates, the various steps in the procedure and estimated timelines are described online.7
5 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety, OJ L 31, 1.2.2002, p. 1.
6 Infant formula means food intended for use by infants during the first months of life and satisfying by itself the nutritional
requirements of such infants until the introduction of appropriate complementary feeding.
7 http://www.efsa.europa.eu/sites/default/files/applications/apdeskapplworkflownutriinfant.pdf
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2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance for the preparation and
presentation of an application for authorisation of an infant and/or follow-on formula manufactured
from protein hydrolysates (EFSA NDA Panel, 2017). Previous EFSA work (EFSA NDA Panel, 2014) and
the regulatory framework8 were also taken into account.
As outlined in the guidance, ‘in order to substantiate the efficacy of a product in reducing the risk
of developing allergy to milk proteins, at least one human intervention study on the incidence of
allergy to milk proteins in the target population for which the formula is intended [. . .] should be
provided’. Similar to health claims, data from studies in animals or other model systems alone cannot
substitute for human data (EFSA NDA Panel, 2016), but ‘should be provided if they may help to
establish the potential of the hydrolysed formula to reduce the risk of developing allergy to milk
proteins’ (EFSA NDA Panel, 2017).
3. Assessment
3.1. Characterisation of the infant formula
The infant formula which is the subject of the dossier is an infant formula marketed in liquid and in
powder form. The protein hydrolysate from which the infant formula is produced is included in Annex I
and II of Commission delegated Regulation (EU) 2016/127 as a suitable protein source for the
manufacture of infant and follow-on formulae.
Protein source of the hydrolysate:
The protein hydrolysate from which the infant formula is manufactured is produced from
demineralised sweet whey protein derived from cow’s milk that is composed of:
• 63% caseino-glycomacropeptide (CMP)-free whey protein isolate with a minimum protein
content9 of 95% of dry matter, and
• 37% sweet whey protein concentrate with a minimum protein content9 of 87% of dry matter.
The demineralised sweet whey protein is used in the further manufacture of the protein hydrolysate
Certificates of analysis for 11 batches of each of the raw materials were provided, i.e. for the whey
protein isolate and the whey protein concentrate mentioned above. Individual intact proteins in whey
have been identified in the dossier. On request from EFSA, the food business operator confirmed that
the information provided on these individual intact proteins is based on publicly available data on
protein composition of whey as presented in Farrell et al. (2004).
Protein processing to obtain the protein hydrolysate:
The protein hydrolysate and the infant formula in which the protein hydrolysate is used are
manufactured under ISO 9001:2015 (quality management systems) and ISO 22000:2005 (food safety
management systems). This is indicated in the certificates provided by the food business operator.
In order to produce the hydrolysate used in this infant formula, a two-stage hydrolysis process is
applied whereby at each stage a trypsin preparation is added to the whey protein solution. Food
enzyme preparations from
that was used to produce the infant formula investigated in the human intervention studies was
presented by the food business operator as directly pertinent to the assessment of the efficacy of the
formula.
The trypsin preparation from porcine pancreas contains trypsin (EC 3.4.21.4.)
(
). On request from EFSA, the food business operator explained
that the trypsin preparation, is added in amounts of at least United
8 https://ec.europa.eu/food/safety/labelling_nutrition/special_groups_food/children_en
9 The content of the crude protein is calculated as Kjeldahl-N 9 6.38.
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States Pharmacopoeia (USP) units/g protein.
Information on the absolute amount of food enzyme, expressed in mg/g substrate protein, has also
been provided by the food business operator and is dependent on the amount of the food enzyme
needed to reach a minimum reference enzyme activity per unit protein substrate weight.
The hydrolytic process is conducted at at a The process is
performed in two hydrolytic steps (i.e. the food enzyme preparation is added twice) with a heat
treatment step ( ) in between to denature the protein that would not yet be
hydrolysed, after which the solution is cooled down again to . The first hydrolytic step has a
duration of and the second a duration of . The hydrolysis is concluded with a heat treatment of
.
This last heat treatment inactivates of trypsin, as documented in a report of one of the
internal laboratories of the food business operator that is certified by ISO 17025:2005 (general
requirements for the competence of testing and calibration laboratories). This report describes the
calibration and provides results for batches of powdered and liquid formula (batches of
unspecified date). It is explained that the internal target is residual active trypsin below
in the finished product, . The
method for the residual trypsin measurement was described by the food business operator. The limits
of quantification obtained from the lowest and highest trypsin concentrations of the calibration curve
correspond to of inactivation of trypsin. The residual activity of was not
measured.
Degree of hydrolysis and molecular weight distribution of peptides, content of free amino
acids and residual proteins in the protein hydrolysate:
Data on the degree of hydrolysis (DH), the molecular weight distribution of peptides and the
residual protein content have been provided only for the final formula (to which free amino acids are
added) and not for the protein hydrolysate. These data are, therefore, described below in the context
of the description of the characteristics of the final infant formula.
With respect to free amino acids in the protein hydrolysate, the food business operator indicated
that no free amino acids are released during the hydrolysis process, due to the endoprotease
specificity of the food enzyme preparation.
Manufacturing process of the infant formula:
In order to produce the powder formula under evaluation, the liquid hydrolysate is pre-heated,
mixed with free amino acids, minerals, vitamins, carbohydrates, oils and optionally nucleotides. It is
then heated again, evaporated, homogenised and evaporated again. Thereafter, additional ingredients
are added before spray drying, as well as afterwards (dry-mixed with the powder) before sieving and
final packing under protective atmosphere.
For liquid formula, which is also the subject of the dossier, after the addition of the last ingredients,
the steps of the second heat treatment, evaporation and spray drying (applied in the case of the
production of the powder) are replaced by sterilisation (ultra-high temperature treatment) before
aseptic homogenisation, and aseptic filling.
Degree of hydrolysis and molecular weight distribution of peptides, content of free amino
acids and residual proteins in the infant formula:
The food business operator based the calculation of the DH on the equation DH (%) = h/
htot 9 100, where h is the number of cleaved peptide bonds and htot is the total number of peptide
bonds present in the proteins before cleavage. The value of h is derived by measuring the increase in
free amino groups in the source material (ANfinal–ANinitial). Free amino nitrogen (AN) is determined by
the reaction with trinitrobenzenesulfonic acid (TNBS),10 and total nitrogen (TN) is determined by the
Kjeldhal method. Free AN and TN before hydrolysis were measured in five batches of each of the
10 TNBS method is an assay of the chromophore specifically formed by the reaction of TNBS with free amino groups.
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source materials (i.e. the sweet whey protein concentrate and the CMP-free whey protein isolate
mentioned earlier) and a weighted average was used. Free AN and TN after hydrolysis were
determined in five batches of the final formula. In order to derive h, the AN/TN values were converted
into mmol/g protein and AN before hydrolysis (ANinitial) was subtracted from AN after hydrolysis
(ANfinal). The total number of peptide bonds in the source material, htot, was derived from the amino
acid analysis of four batches of each of the source materials, as sum of the mmol amino acids/g
protein. The Panel notes that ANfinal was measured in the formula which contains additional free amino
acids instead of in the protein hydrolysate. Therefore, the Panel notes that the data presented by the
food business operator do not represent DH and are only considered to approximate DH. Data have
been provided for five different formula brands (one sample each) containing the protein hydrolysate,
showing values in the range of .
Detailed descriptions of the internal methods of analyses of free AN and TN used, the
corresponding validation files and the analysis table for the batches of the source materials and final
formula were submitted by the food business operator. Amino acids were analysed using in-house
methods in a laboratory of the food business operator that is accredited for this analysis (certificate of
accreditation ISO 17025:2005 ‘general requirements for the competence of testing and calibration
laboratories’ provided).
In the original dossier, with respect to residual individual intact proteins in the protein hydrolysate,
an analysis using sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) of one batch
of the final infant formula, compared with protein standards, showed that no and
peptides/proteins above the molecular weight of were present in the formula (the SDS–PAGE
method was described). However, according to a new more sensitive method, i.e. lithium dodecyl
sulfate–polyacrylamide gel electrophoresis (LDS–PAGE) provided by the food business operator,
. The validated method is not
quantitative and the limit of detection was not formally assessed, but given at 1–2.5 mg/kg equivalent
protein by the food business operator.
The food business operator also provided several experiments aimed at demonstrating a reduced
content of in the formula. The levels of measured by ELISA were
below 0.8 mg equivalent/g equivalent protein which was a pre-specified threshold set by the food
business operator. This threshold was chosen to comply with the criteria laid down in Annex IV of
Commission Directive 2006/141/EC, i.e. less than 1% of nitrogen containing substances in the
formulae should be immunoreactive protein. In addition, an experiment measuring the residual
in response to the formula compared with intact .
Although
, there was considerable variability within the groups receiving the
formula. This prevents any definitive conclusion being drawn from the on the
allergenicity of the formula. Although
, the Panel notes that though detectable by LDS-PAGE, has not been
quantified and other allergenic proteins present in whey have not been investigated (e.g.
).
The molecular weight distribution of peptides in the final formula (to which free amino acids are
added, depending on regulatory requirements) was analysed by size-exclusion chromatography with UV
detection, as described in the publication by Johns et al. (2011). The chromatographic column used was
a on an Agilent 1260 HPLC system and with a UV wavelength of .
However, the analytical method applied by the food business operator differed from the published
method in the use of different protein and peptide standards to calibrate the elution time axis. The food
business operator explained that a calibration was obtained considering the elution time of a number of
standard proteins, peptides and free amino acids. Data on the molecular weight distribution in
batches of the commercial and prototype protein formulae used ( ) from
different production sites were provided. Based on these data, the food business operator derived the
following target ranges for the molecular weight distribution of peptides in the final infant formula:
< 1,000 Da:
1,000–2,500 Da:
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2,500–5,000 Da:
> 5,000 Da:
The Panel notes that the ranges presented by the food business operator within each of the
molecular weight categories are very broad. The variability in size distribution of the peptides within
the individual categories that may be encountered may have an impact on the presence of the
epitopes of allergens which, as a consequence, may vary between different batches of the formula.
Therefore, the Panel considers that the data provided are insufficient to characterise the protein
hydrolysate in relation to the effect that is claimed, i.e. the reduction of the risk of developing atopic
dermatitis in infants with a family history of allergy.
The batch-to-batch variability of the molecular weight distribution of peptides as well as the
average peptide size distribution over time (based on historical data) of the protein hydrolysate for
each of the food enzyme preparations could not be provided by the food business operator
However, data were provided for 5 or 6
independently produced batches of formula per food enzyme preparation (no certificate of analysis
was provided). The protein content of the formulae (both powder and liquid) is 1.9 g/100 kcal (1.27 g/
100 mL). The amino acid profile of the infant formula complies with the profile described in Annex IIIB
of Regulation (EU) No 2016/127, which was established for this formula when it was included in the
Annex to the before-mentioned Regulation.
With respect to Maillard reaction products, the internal release norms for reactive11 and blocked12
lysine in the final liquid and powdered formula, measured by ion-exchange chromatography according
to an internal method (described by the applicant and presented as validated in-house), have been
provided in the dossier.
The contents of alpha-linolenic acid (ALA), docosahexaenoic acid (DHA), iodine and vitamin D
correspond to the required content according to Directive 2006/141/EC. The nutrient content of all
other nutrients of the formula is in line with Regulation (EU) No 2016/127.
With respect to stability, the food business operator explains that a number of samples from each
manufacturing batch are always analysed at the end of shelf-life, according to internal standards.
Products are stored in their original pack, in rooms at 20°C with the humidity considered
representative of the yearly average climate conditions of the geographical area in which the formula
is sold.
The Panel considers that, in relation to the effect that is claimed, the infant formula under
evaluation is not sufficiently characterised with respect to the molecular weight distribution of peptides.
3.2. Efficacy of the formula in reducing the risk of developing atopic
dermatitis in infants with a family history of allergy
The food business operator provided results of three human intervention studies reported in nine
publications as directly pertinent to the assessment of the efficacy of the formula (Vandenplas et al.,
1992, 1995; Marini et al., 1996; von Berg et al., 2003, 2007, 2008, 2010, 2013, 2016). None of them
were claimed proprietary by the food business operator hence none were accompanied by their study
reports. The food business operator also provided, as supportive evidence, 11 human studies and 12
animal studies.
As described in the scientific and technical guidance (EFSA NDA Panel (2017)), ‘the Panel cannot
set specific requirements with respect to the duration of the intervention and/or the duration of the
follow-up. However, the Panel considers that reducing the risk of developing allergy during at least the
first year of life would be clinically significant for the target population. Claims on the reduction of the
risk of allergic disease for longer periods of time would require longer follow-ups’.
Study by Vandenplas et al.
The study reported in Vandenplas et al. (1992, 1995) was described as a randomised study with a
follow-up of five years without providing information on the methodology used for randomisation.
Following a request from EFSA to provide additional information with respect to the randomisation
procedure, the food business operator provided some clarifications they received from the authors of
the study. These indicated that subjects were allocated to groups in a non-random manner (exact
11 Lysine present in proteins/peptides with a free amino group.
12 Lysine present in proteins/peptides for which the amino group has reacted with reducing sugars.
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methodology claimed confidential). The Panel considers that no conclusion can be drawn from this
non-randomised study for the scientific substantiation of the effect.
Study by Marini et al.
The study by Marini et al. (1996) was described as a randomised, single-blinded (caregivers were
aware of the group allocation) controlled trial. The trial was carried out in infants with two atopic
parents and who were either fed the formula under evaluation or a control formula manufactured from
intact cow’s milk protein. Details on the randomisation procedure were neither provided in the
publication nor provided by the food business operator upon request from EFSA. Randomisation took
place once formula-feeding was introduced. The publication reports that 279 infants were enrolled in
the study. According to the food business operator, 155 were randomised to formula-feeding (either
intervention or control), while 124 were included in an exclusively breast-fed reference group.
Atopic dermatitis was diagnosed according to Moore et al. (1985), when scaly, erythematous and
itchy eczematous rash was localised in at least two of the following areas: face and scalp, behind the
ears and at the flexural folds.
Results are presented in the publication in terms of cases of atopic dermatitis in subgroups of
infants who were exclusively formula-fed, those who received breast milk in addition to the two study
formulae (around 63% of all formula-fed infants; separated by study formula) and those who were
exclusively breast-fed. No statistical analyses were presented on these subgroups.
A multivariable logistic regression analysis was presented in the paper, in which feeding intact cow’s
milk formula showed higher odds for developing atopic dermatitis at 1 year of age (odds ratio (OR)
3.2, 95% confidence interval (CI) 1.1; 9.2). However, the Panel notes that it is unclear to which
feeding this was compared and whether exclusively breast-fed infants were part of this analysis or not.
A factor called ‘breast/hydrolysed feeding’ (with an unclear comparator) was not statistically
significantly related to the health outcome atopic dermatitis and no separate analysis was presented
for the intervention formula. No results were presented for the outcome at 2 and 3 years of age, when
it was also assessed. The Panel notes that it is unclear for which covariates the analysis was adjusted.
The Panel also notes that no correction for multiple statistical comparisons was made in the analysis of
this study, in which the primary endpoint had not been specified and multiple study parameters were
investigated.
The Panel considers that, owing to the methodological limitations of this study and the associated
analysis, i.e. single-blind study design, unclear randomisation procedure and unclear statistical analysis,
no conclusion can be drawn from this study for the scientific substantiation of the effect.
GINI study
The German Infant Nutritional Intervention (GINI) study (von Berg et al., 2003, 2007,
2008, 2010, 2013, 2016) was a randomised, controlled, double-blind, two-centre intervention study. It
was undertaken on healthy term infants less than 14 days of age, with a birthweight ≥ 2,500 g, with
at least one family member (mother, father or sibling) with an atopic disease, and with no prior
consumption of cow’s milk-based formula. In this study, three different formulae manufactured from
hydrolysed protein, among them the formula under evaluation, were compared with a formula
manufactured from intact cow’s milk protein with respect to their effect on reducing the risk of
developing atopic manifestations.
The Panel notes that von Berg et al. (2003) reports for the formula under evaluation the
percentage of peptides in the fractions < 1,500 Da as 54% and in the fraction of > 6,000 Da as 18%.
This contrasts with the target ranges for the molecular weight distribution of peptides of the formula
provided by the food business operator. According to these target ranges, of all peptides are
in the fraction of > 5,000 Da. Upon request from EFSA, the food business operator explained that the
article by von Berg et al. (2003) contains no information on the analytical methods used to assess the
molecular weight distribution of peptides and therefore, it is not possible to compare the results
reported by von Berg et al. (2003) with the target ranges used by the food business operator. The
food business operator states that the production process of the infant formula used in the study by
von Berg et al. (2003) is identical to the one described in the dossier. The Panel considers that, based
on the information available, it cannot be ascertained that the formula used in the study by von Berg
et al. (2003) was the same as the one under evaluation.
Randomisation of study participants was performed based on a computer-generated list, stratified
by single or double heredity (parents only) of atopy and study site. The Panel notes that insufficient
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information was provided in the publications on whether the allocation of subjects to groups was
appropriately concealed or not.
Mothers in all groups were encouraged to exclusively breast-feed for at least 4 months, but
preferably for 6 months. Study formula could be introduced at the discretion of the mother and was
provided up to 6 months of age. Regarding blinding, study formulae were identically labelled and
coded with four different letters for each of the four formulae. Caregivers were advised not to
introduce complementary foods before 4 months of age. They were asked, when complementary
feeding was to be started, not to introduce more than one food per week and to avoid dairy products,
hen’s egg, soy, fish, nuts, tomatoes and citrus fruits during the first year of life. The type of milk fed in
the first 6 months of life and the timing of introduction of complementary foods was assessed through
weekly diaries kept by caregivers and cross-checked by structured interviews.
In von Berg et al. (2003), it is reported that clinical examinations were carried out at 1, 4, 8 and 12
months of age together with a structured interview conducted by a study physician to elicit information
on the presence or absence of diagnostic criteria for atopic dermatitis modified from Hanifin and Rajka
(1980). These criteria were ‘1) typical morphology and distribution of skin lesions (face, neck and
scalp, flexural folds, hands, and extensor sides of the extremities); 2) pruritus (signs of scratching);
and 3) tendency toward chronicity (duration ≥ 14 days, chronically relapsing, or both)’. The fulfilment
of the criteria was cross-checked by a second specifically trained allergologist. The Panel understands
that only if both physicians agreed on the fulfilment of all three criteria, atopic dermatitis was
diagnosed.
In von Berg et al. (2008), it is described that at, and after the age of one year up to 15 years (i.e.
at 1, 2, 3, 4, 6, 10 and 15 years of age), the diagnosis of atopic dermatitis was based on caregivers’
reports on physician’s diagnosis using a modification of the International Study of Asthma and Allergies
in Childhood (ISAAC) questionnaire. EFSA requested the food business operator to clarify whether the
ascertainment of atopic dermatitis at 1 year of age was based on a physician’s diagnosis or caregivers’
reports of symptoms and whether the outcome ascertainment was different in von Berg et al. (2003,
2008). In response to this last request, EFSA received a letter from the investigators of the GINI study
in which it was clarified that both methods of outcome ascertainment (i.e. physician’s diagnosis and
caregivers’ reports) were used at 1, 2 and 3 years of age. The investigators also provided a cumulative
analysis of incident cases of atopic dermatitis based on clinical diagnosis by the study physicians in the
population of children with complete follow up until 3 years of age.
The Panel notes the potential bias that is introduced into the outcome ascertainment based on
caregivers’ reports of symptoms. Therefore, the Panel does not consider it as an adequate method of
assessing the development of atopic dermatitis. As a consequence, no conclusions can be drawn from
the analyses at time points where the outcome assessment was based only on caregivers’ reports of
symptoms, i.e. all analyses after three years of age. The results from these time points are therefore
not reported in the present opinion.
The primary outcome of the study was the presence of atopic manifestations (i.e. at least one of
the following: atopic dermatitis, allergic urticaria or food allergy with manifestations in the
gastrointestinal tract) at 1 year of age. Sample size calculations were based on the following
assumptions: 1) infants exclusively breast-fed or who drop-out during the study would approximately
amount to 50% and 2) the prevalence of atopic manifestations at the end of the study in the
intervention and control groups would be 30% and 20%, respectively. To obtain a power of 80% at a
two-sided significance level of 5%, 600 infants per group had to be enrolled (without considering drop-
outs and exclusively breast-fed infants 313 infants had to be included).
Finally, 557 infants were randomised to the group receiving the formula under evaluation
(intervention group) and 556 to the formula manufactured from intact cow’s milk protein (control
group). According to the publication by von Berg et al. (2003), 315 and 328 infants received the study
formulae, 269 and 286 completed the 12 months follow-up, and 241 and 256 were compliant with the
study protocol (i.e. per protocol (PP) population). In subsequent publications on the same study
population (von Berg et al., 2008, 2010, 2013), the number of infants included in the PP population
was not corroborated. Following a request from EFSA to clarify this discrepancy, the food business
operator indicated that the PP population in this study also included subjects with missing data at
intermediate time points. Therefore, the food business operator explained that the number of subjects
in the PP population was variable and could increase from one assessment time point to the next,
depending on whether a measurement was available or not.
For the analysis at 1 year of age (von Berg et al., 2003), the reasons for drop-outs were given
overall for all four study groups together, with an indication that no significant differences between
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groups were observed. A total of 42% of infants were exclusively breast-fed during the first four
months of age and not considered in the PP analysis. The exclusively breast-fed infants (that were
excluded from the analysis) differed in characteristics from those who had received formula with
respect to the following: higher prevalence of atopic dermatitis in the family, higher rate of caesarean
section, higher parental education, higher number of siblings, higher number of mothers older than 30
years of age, less smoking mothers, less homes with pets, and less participants from one of the study
sites. Following a request from EFSA to comment to what extent the principle of randomisation is still
respected with removal of this high number of subjects, the food business operator indicated that
exclusively breast-fed infants were equally distributed among groups and that all but 3% of those
were followed-up and included in the intention-to-treat (ITT) analysis, which showed results in the
same direction as the PP analysis.
Baseline characteristics of the PP population were presented (von Berg et al., 2003). No statistically
significant differences were observed between the study groups.
No statistically significant effect of consumption of the formula under evaluation was observed on
the primary outcome of the study, i.e. on the risk of developing atopic manifestations at 1 year of age
(von Berg et al., 2003) and on the cumulative incidence of developing atopic manifestations at 3 years
of age (von Berg et al., 2007).
Atopic dermatitis, one of the secondary outcomes of the study, was diagnosed at 1 year of age, as
reported in von Berg et al. (2003), in 22/241 infants in the intervention and 38/256 infants in the
control group in the PP population (crude OR [95% CI] calculated by EFSA: 0.58 [0.33; 1.01];
adjusted OR 0.56 [0.32; 0.99], multivariable logistic regression, adjusted in the final model for sex,
family history of atopic dermatitis and maternal smoking after pregnancy).
According to the letter from the investigators to EFSA, an additional 15 incident cases diagnosed by
the study physician occurred during the second and third year of life in the intervention group and 17
in the control group, in those participants who had a complete three-year follow-up (i.e. n = 229 in the
intervention and n = 245 in the control group). The adjusted OR for the cumulative incidence of atopic
dermatitis, diagnosed by a study physician, from birth to 3 years was 0.60 (95% CI 0.37–0.97;
adjusted for the same covariates as the analysis reported above). Breast-feeding as a covariate was
not considered in the analysis at 1 year of age, but was included in the analysis as a possible covariate
at 3 years of age, without showing statistical significance.
Results for the ITT population (both including and excluding exclusively breast-fed infants) for the
prevalence of atopic dermatitis in the first year of life and for the cumulative incidence from birth to
three years of age were not statistically significant (von Berg et al., 2007).
No correction for multiple comparisons was carried out for either the ITT or the PP analysis. EFSA
requested the food business operator to clarify to what extent conclusions can be drawn from this
analysis for the substantiation of the effect, considering that atopic dermatitis was not the primary
outcome of the study and that the analysis was not corrected for multiple comparisons. Following this
request, the food business operator replied that atopic dermatitis was one of the composite outcomes
of atopic manifestations, the primary outcome of the study, and that correcting for multiple
comparisons of these correlated outcomes would have led to an overly conservative approach. The
Panel notes that there are statistical methods and testing strategies available that allow accounting for
the testing of multiple correlated outcomes. The Panel also notes that, in the absence of appropriate
corrections, it cannot be excluded that the statistically significant findings of the study with respect to
the risk of developing atopic dermatitis is due to the increase in the type 1 error rate associated with
carrying out multiple statistical tests.
The Panel notes the methodological limitations of the study with regard to the evaluation of an
effect of the formula on the reduction in risk of developing atopic dermatitis (i.e. exclusion of a
substantial percentage, 42%, of randomised subjects from PP analyses, all exclusively breast-fed
infants, and lack of correction for multiple statistical testing, outcome ascertainment after the age of
three years based on caregivers’ reports only). The Panel also notes the uncertainty as to whether or
not the formula investigated in the study was the same as the formula under evaluation described in
Section 3.1. Thus, the Panel considers that no conclusions can be drawn from this study for the
scientific substantiation of the effect.
Additional information provided:
The food business operator also presented random effects meta-analyses on the three studies
described above and on five studies, including the previous three and two additional studies that were
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presented as supportive evidence. The Panel notes that, in the absence of conclusions that can be
drawn from the individual studies, no conclusions can be drawn from a meta-analysis thereof.
Eleven human studies provided by the food business operator as supportive evidence all compared
the formula under evaluation to formulae manufactured from intact cow’s milk protein, unless
otherwise stated in the description below. The Panel notes that none of these 11 human studies,
presented as supportive evidence, enabled conclusions to be drawn on the effect of the formula on the
reduction of risk of developing atopic dermatitis. The reasons are outlined in the following.
– Becker et al. (2004) described a multifaceted allergy intervention (i.e. encasement of
mattresses, instructions for washing bedsheets, cleaning of carpets and furniture, keeping
pets outside the house, smoking cessation, avoidance of day care, breast-feeding or use of
the formula under evaluation), but did not report on the effect of the formula under
evaluation and on atopic dermatitis separately from atopy.
– It is unclear whether the study described in the paper by D’Agata et al. (1996) was a non-
randomised intervention or an observational study. The investigated outcome was eczema
that was not defined, and it is unclear whether this was eczema of all origins or atopic
dermatitis.
– de Seta et al. (1994) investigated an outcome that was a combination of atopic dermatitis
and cow’s milk intolerance, rather than atopic dermatitis alone.
– Exl et al. (2000) presented an analysis in infants fed the formula under evaluation vs intact
cow’s milk formula, in a non-randomised study. In addition, the intervention consisted of
delaying allergen introduction in general and not only of the formula under evaluation. Also,
the outcome that was assessed was ‘skin symptoms’ that included, but was not limited to,
atopic dermatitis.
– The study by Fukushima et al. (1997) was not randomised and the diagnosis of atopic
dermatitis was based on caregivers’ reports in questionnaires, which is not considered by the
Panel as an adequate method of outcome ascertainment.
– The study reported in Iikura et al. (1995) and Akimoto et al. (1997) was not randomised and
the outcome that was investigated was ‘atopic-dermatitis-like symptoms’. It is unclear whether
this covered only atopic dermatitis or also other skin diseases.
– Lowe et al. (2011), in an RCT, investigated doctor-diagnosed eczema or any rash that was
treated with topical steroid preparation, rather than specifically atopic dermatitis.
– Tsai et al. (1991) carried out an unblinded RCT.
– Vandenplas et al. (1988, 1989) reported on a non-randomised intervention study on
dermatological symptoms rather than atopic dermatitis.
– Equally, the study by Sun et al. (2015) was not randomised and atopic dermatitis was
diagnosed based on caregivers’ reports of a physician’s diagnosis, which is not considered by
the Panel as an adequate method of outcome ascertainment.
– Finally, the study by Willems et al. (1993) was not appropriately randomised. The outcome
that was investigated was not further defined eczema, and it is unclear whether this was
eczema of all origin or atopic dermatitis.
The Panel notes that, among the 14 human intervention studies provided, no human intervention
studies have been submitted from which conclusions could be drawn for the scientific substantiation of
the effect. In the absence of evidence from human clinical studies on the effect of the infant formula
in reducing the risk for developing atopic dermatitis, the Panel notes that the animal studies that were
also submitted cannot be used for the scientific substantiation of the effect.
The Panel concludes that a cause-and-effect relationship has not been established between the
consumption of the infant formula under evaluation and a reduction in the risk of developing atopic
dermatitis in infants with a family history of allergy.
4. Conclusions
The Panel concludes that:
• in relation to the effect that is claimed, the infant formula under evaluation is not sufficiently
characterised with respect to the molecular weight distribution of peptides;
• a cause-and-effect relationship has not been established between the consumption of the
infant formula under evaluation and a reduction in the risk of developing atopic dermatitis in
infants with a family history of allergy.
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5. Documentation as provided to EFSA
Dossier on the Efficacy of Nestle’s Infant Formulas Manufactured from Partially Hydrolysed 100%
Whey Protein in Reduction of the Risk of Developing Atopic Dermatitis. December 2019. Submitted by
Societe des Produits Nestle S.A.
Steps taken by EFSA
1) The technical dossier was received by EFSA on 19/07/2019.
2) A letter from the European Commission with the request for a scientific opinion on the safety
and suitability for use by infants of an infant and follow-on formula manufactured from protein
hydrolysate was received by EFSA on 09/08/2019.
3) The scientific evaluation procedure started on 20/01/2020.
4) On 26/02/2020, the Working Group on Food Allergy of the NDA Panel agreed on a list of
questions for the food business operator to provide additional information to accompany the
dossier. The scientific evaluation was suspended on 13/03/2020 and was restarted on 16/04/
2020.
5) On 24/04/2020, the Working Group on Food Allergy of the NDA Panel agreed on a list of
questions for the food business operator to provide additional information to accompany the
dossier. The scientific evaluation was suspended on 14/05/2020 and was restarted on 19/06/
2020.
6) On 07/05/2020, additional information was spontaneously submitted by the study group of
one of the human intervention studies provided by the food business operator.
7) On 28/09/2020, the Working Group on Food Allergy of the NDA Panel agreed on a list of
questions for the food business operator to provide additional information to accompany the
dossier. The scientific evaluation was suspended on 15/10/2020 and was restarted on 17/12/
2020.
8) On 22/01/2021, the Working Group on Food Allergy of the NDA Panel agreed on a list of
questions for the food business operator to provide additional information to accompany the
dossier. The scientific evaluation was suspended on 01/02/2021 and was restarted on 15/02/
2021.
9) During its meeting on 27-29/04/2021, the NDA Panel, having evaluated the data, adopted an
opinion on 29/04/2021.
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CEF EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CEP EFSA Panel on Food Contact Materials, Enzymes and Processing Aids
CI confidence interval
CMP caseino-glycomacropeptide
DH degree of hydrolysis
DHA docosahexaenoic acid
EC number Enzyme Classification Number of Enzyme Commission of the International Union of
Biochemistry and Molecular Biology
ELISA enzyme-linked immunosorbent assay
GINI German Infant Nutritional Intervention
h number of cleaved peptide bonds
HPLC high-performance liquid chromatography
htot total number of peptide bonds
IgE immunoglobulin E
ISAAC The International Study of Asthma and Allergies in Childhood
ISO International Organization for Standardization
ITT intention-to-treat
LDS–PAGE lithium dodecyl sulfate–polyacrylamide gel electrophoresis
MW molecular weight
NDA EFSA Panel on Nutrition, Novel Foods and Food Allergens
OR odds ratio
PP per protocol
RCT randomised controlled trial
SDS–PAGE sodium dodecyl sulfate–polyacrylamide gel electrophoresis
TN total nitrogen
TNBS trinitrobenzenesulfonic acid
USP United States Pharmacopeia
UV ultraviolet
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